CN106236826A - A kind of lactic acid bacteria teichoic acid gel for vagina auxiliary treatment - Google Patents
A kind of lactic acid bacteria teichoic acid gel for vagina auxiliary treatment Download PDFInfo
- Publication number
- CN106236826A CN106236826A CN201610660251.1A CN201610660251A CN106236826A CN 106236826 A CN106236826 A CN 106236826A CN 201610660251 A CN201610660251 A CN 201610660251A CN 106236826 A CN106236826 A CN 106236826A
- Authority
- CN
- China
- Prior art keywords
- lactic acid
- parts
- acid bacteria
- vagina
- gel
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/488—Pueraria (kudzu)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/80—Polymers containing hetero atoms not provided for in groups A61K31/755 - A61K31/795
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
Abstract
The present invention provides a kind of lactic acid bacteria teichoic acid gel for vagina auxiliary treatment, is formed by the following ingredients in units of weight portion is refined: lactic acid bacteria lipoteichoic acid 15 parts, Oligomeric maltose 10 50 parts, powder of Radix Puerariae 20 100 parts, hyaluronic acid 5 50 parts, glycerol 5 10 parts, distilled water 500 5000 parts.In the present invention, contained lactic acid bacteria lipoteichoic acid can be sticked with vaginal epithelial cell receptor, captures ecological site, thus suppresses sticking of pathogenic bacterium；Meanwhile, if isoflavone contained in powder of Radix Puerariae can be combined performance estrogen action with Estrogen receptor with low affinity, thus promote vaginal mucosal epithelium hypertrophy, reduce vaginal pH, reach to repair vaginal injury, increase elastic effect.
Description
Technical field
The present invention relates to a kind of lactic acid bacteria teichoic acid gel for vagina auxiliary treatment, belong to Amino-Cerv technology
Field.
Background technology
Vagina is an extremely complex microecosystem, its be by the solution of vagina dig structure, Tiny ecosystem flora,
Local immune system and endocrine regulation function collectively form.Women suffer from vaginal infection disease mainly by the cause of disease,
Environment and the domination of host's these three factor, but it it is critical only that the mutual relation between normal microbial flora and host.
For in terms of clinical medicine, microecology in vaginas of women and vagina occur the relation infected the closest.For at present, antibacterial
The effect that bacterial vaginosis treated clinically by medicine such as metronidazole etc. is preferable, but still some case is to medicine
Produce drug resistance, and medicine also has certain toxic and side effects；Additionally, use antibacterial drug therapy to be killed by pathogen only,
Microecology in vaginas environment can not be recovered, therefore use the treatment of this method to tend to recurrence.Estrogen was the most once widely used in
Vagina is treated, but owing to its sphere of action is wide, side effect strong, therefore and nonideal control may result in the diseases such as breast carcinoma,
Treat medicine.
Phytoestrogen can be considered the exogenous hormones of the mankind and other mammals, and the endocrine directly participating in body is adjusted
Joint.On the one hand, the phytoestrogen of doses can be combined with estrogen receptor in vivo, plays estrogen-like effects；From
And promote vaginal mucosal epithelium hypertrophy, reduce vaginal pH, reach to repair vaginal injury, increase elastic effect.It is reported, plant
In thing estrogen during dosage, certain estrogen activity can be produced；During high dose, can activate because estrogen level limits not
The estrogen receptor that can activate, generation estrogen is potent should；When phytoestrogen uses enough dosage, can produce and body
The usefulness that interior 17 β estradiol are similar.Although being referred to as phytoestrogen, but the chemical nature of Radix Puerariae isoflavone non-hormone
Material, its structure is similar to the estrogen in women body, therefore can play simulation, interference, the life of two-ways regulation Endocrine Levels
Reason effect.On the other hand, phytoestrogen can't produce the adverse side effect that estrogen brings.
In addition to recovering vaginal environment, treatment vagina also needs to recover microecology in vaginas balance.Lactic acid bacteria is vagina
Antibacterial most commonly seen in Tiny ecosystem, it is the resident bacterium in healthy women vagina and dominant bacteria, and it is in vaginal secretions
Separation rate reaches more than 80%, plays the most crucial effect to keeping microecology in vaginas balance.Bacterial vaginosis is suffered from
For person, it need to be helped to recover the dominant microflora status of lactic acid bacteria, but about the safety of lactobacillus vaginal capsule, adaptability still
Without clearly coming to a conclusion, curative effect is the most unstable.Therefore, the present invention is from helping the primary lactic acid bacteria of vagina to capture the vagina Ecological niche, thus presses down
Pathogenic bacterium processed set out in the angle of vagina field planting, use lactic acid bacteria lipoteichoic acid to stick with vaginal epithelial cell receptor, account for
The ecological site of neck, thus suppress sticking of pathogenic bacterium, recover the growth of vagina lactic acid bacteria thus reach to treat the purpose of disease.
Summary of the invention
It is an object of the invention to provide a kind of lactic acid bacteria teichoic acid gel for vagina auxiliary treatment, be suitable for the moon
Tract disease patient uses.
For achieving the above object, the present invention adopts the following technical scheme that
A kind of lactic acid bacteria teichoic acid gel for vagina auxiliary treatment, it is characterised in that: include following raw material:
Lactic acid bacteria lipoteichoic acid 1-5 part, Oligomeric maltose 10-50 part, powder of Radix Puerariae 20-100 part, hyaluronic acid 5-50 part, glycerol 5-10
Part, distilled water 500-5000 part.
Preferably, including following raw material: lactic acid bacteria lipoteichoic acid 3 parts, Oligomeric maltose 50 parts, powder of Radix Puerariae 50
Part, hyaluronic acid 30 parts, glycerol 10 parts, distilled water 5000 parts.
A kind of lactic acid bacteria teichoic acid gel for vagina auxiliary treatment, its preparation process is as follows:
(1) lactic acid bacteria lipoteichoic acid: lactic acid bacterial liquid is centrifugal collects thalline, takes out after being placed in liquid nitrogen freezing 1min, and room temperature is put
Putting 90s, such multigelation 3-5 time is with broken thalline；Add 20% phenol solution reaction 5min of 2 times of volumes of thalline, then add
Entering 95% phenol solution of equivalent, water-bath 30min at 68 DEG C, period is stirred continuously；After taking-up, reactant liquor is cooled to 10 DEG C,
7000rpm is centrifuged 15min；Draw upper solution to be placed in bag filter, flowing water dialysis 24-48h；Dialysis is stood again with distilled water
24-48h, period renews distilled water every 6h；It is eventually adding the polyethylene glycol 6000 of 4% w/v, solution is concentrated into original volume
1/4；Add the Dnase I of 5% w/v, enzymolysis 0.5-1h at 37 DEG C, 80 DEG C of heating 5-10min enzyme denaturing；8000rpm is centrifuged 10-
15min；Taking supernatant, add the acetone of 2 times of volumes, overnight precipitation, 200rpm is centrifuged 2min and i.e. can get lactic acid bacteria teichoic acid.
(2) preparation of lactic acid bacteria lipoteichoic acid gel: by lactic acid bacteria lipoteichoic acid, Oligomeric maltose, powder of Radix Puerariae, hyalomitome
Acid and glycerol are sufficiently mixed according to aforementioned proportion, add distilled water pelletize 10min, make the gel of a diameter of 5-8mm.
Phytoestrogen: phytoestrogen can be considered the exogenous hormones of the mankind and other mammals, directly participates in machine
The endocrine regulation of body.On the one hand, the phytoestrogen of doses can be combined with estrogen receptor in vivo, plays female sharp
Element sample effect；Thus promote vaginal mucosal epithelium hypertrophy, reduce vaginal pH, reach to repair vaginal injury, increase elastic work
With.It is reported, in phytoestrogen during dosage, certain estrogen activity can be produced；During high dose, can activate and swash because of female
Element level limits the estrogen receptor failing to activate, and generation estrogen is potent should；When phytoestrogen uses enough dosage,
The usefulness similar to internal 17 β estradiol can be produced.Although being referred to as phytoestrogen, but the chemistry of Radix Puerariae isoflavone is originally
Matter not hormonal substance, its structure is similar to the estrogen in women body, therefore can play in simulation, interference, two-ways regulation
The physiological action of secretion level；Meanwhile, phytoestrogen can't produce the adverse side effect that estrogen brings.
Lactic acid bacteria lipoteichoic acid: lactic acid bacteria lipoteichoic acid has the characteristic of low isoelectric point, IP, can be formed relatively in vaginal environment
Many negative charges, are sticked with vaginal epithelial cell receptor by electrostatic attraction, capture ecological site, thus suppress pathogenic bacterium
Stick, recover vagina lactic acid bacteria growth thus reach treat disease purpose.Additionally, due to the fat phosphorus used in the present invention
Teichaic acid derives from lactic acid bacteria, and lactic acid bacteria inherently vagina resides microorganism, thus without producing untoward reaction.
It is an advantage of the current invention that:
First, the present invention uses the phytoestrogen gentleer than estrogen action for the reparation of vaginal injury, it is to avoid female swash
The adverse side effect that element brings.Phytoestrogen can be considered the exogenous hormones of the mankind and other mammals, can directly participate in
The endocrine regulation of body.On the one hand, the phytoestrogen of doses can be combined with estrogen receptor in vivo, plays female
Hormone-like effect；Thus promote vaginal mucosal epithelium hypertrophy, reduce vaginal pH, reach to repair vaginal injury, increase elasticity
Effect.On the other hand, during high dose, can activate because estrogen level limits the estrogen receptor failing to activate, produce female sharp
Element is potent should；When phytoestrogen uses enough dosage, the usefulness similar to internal 17 β estradiol can be produced.This
Bright middle use phytoestrogen Radix Puerariae isoflavone carries out two-ways regulation to the vagina endocrine suffering from vagina, not only
It is of value to the recovery of intravaginal environment, and avoids the side effect that estrogen brings
Secondly, the present invention uses lactic acid bacteria lipoteichoic acid to help primary lactobacter growth, thus recovers microecology in vaginas balance.
Lactic acid bacteria is antibacterial most commonly seen in microecology in vaginas, and it is the resident bacterium in healthy women vagina and dominant bacteria, to holding
Microecology in vaginas balance plays the most crucial effect.For bacterial vaginosis patient, it need to be helped to recover lactic acid
The dominant microflora status of bacterium, but safety, the adaptability about lactobacillus vaginal capsule there is no and clearly come to a conclusion, and curative effect is the most unstable
Fixed.Therefore, the present invention is from helping the primary lactic acid bacteria of vagina to capture the vagina Ecological niche, thus suppresses pathogenic bacterium at the angle of vagina field planting
Degree sets out, and uses lactic acid bacteria lipoteichoic acid to stick with vaginal epithelial cell receptor, captures ecological site, thus suppression is caused a disease
Sticking of bacterium, reach to recover the growth of vagina lactic acid bacteria thus reach the purpose for the treatment of disease.The lipoteichoic acid that the present invention uses
Deriving from lactic acid bacteria, lactic acid bacteria inherently vagina resides microorganism, thus without producing untoward reaction.
Detailed description of the invention
Embodiment 1
A kind of lactic acid bacteria teichoic acid gel for vagina auxiliary treatment, including following raw material: lactic acid bacteria fat phosphorus
Teichaic acid 3 parts, Oligomeric maltose 50 parts, powder of Radix Puerariae 50 parts, hyaluronic acid 30 parts, glycerol 10 parts, distilled water 5000 parts.
Its preparation process is as follows:
(1) lactic acid bacteria lipoteichoic acid: lactic acid bacterial liquid is centrifugal collects thalline, takes out after being placed in liquid nitrogen freezing 1min, and room temperature is put
Putting 90s, such multigelation 4 times is with broken thalline；Add 20% phenol solution reaction 5min of 2 times of volumes of thalline, add
95% phenol solution of equivalent, water-bath 30min at 68 DEG C, period is stirred continuously；After taking-up, reactant liquor is cooled to 10 DEG C,
7000rpm is centrifuged 15min；Draw upper solution to be placed in bag filter, flowing water dialysis 36h；Dialysis 36h is stood again with distilled water,
Period renews distilled water every 6h；It is eventually adding the polyethylene glycol 6000 of 4% w/v, solution is concentrated into the 1/4 of original volume；Add
Enter the Dnase I of 5% w/v, enzymolysis 1h at 37 DEG C, 80 DEG C of heating 10min enzyme denaturing；8000rpm is centrifuged 15min；Take supernatant, add
The acetone of 2 times of volumes, overnight precipitation, 200rpm is centrifuged 2min and i.e. can get lactic acid bacteria teichoic acid.
(2) preparation of lactic acid bacteria lipoteichoic acid gel: by lactic acid bacteria lipoteichoic acid, Oligomeric maltose, powder of Radix Puerariae, hyalomitome
Acid and glycerol are sufficiently mixed according to aforementioned proportion, add distilled water pelletize 10min, make the gel of a diameter of 5mm.
Embodiment 2
A kind of lactic acid bacteria teichoic acid gel for vagina auxiliary treatment, including following raw material: lactic acid bacteria fat phosphorus
Teichaic acid 1 part, Oligomeric maltose 10 parts, powder of Radix Puerariae 20 parts, hyaluronic acid 5 parts, glycerol 5 parts, distilled water 500 parts.
Its preparation process is as follows:
(1) lactic acid bacteria lipoteichoic acid: lactic acid bacterial liquid is centrifugal collects thalline, takes out after being placed in liquid nitrogen freezing 1min, and room temperature is put
Putting 90s, such multigelation 3 times is with broken thalline；Add 20% phenol solution reaction 5min of 2 times of volumes of thalline, add
95% phenol solution of equivalent, water-bath 30min at 68 DEG C, period is stirred continuously；After taking-up, reactant liquor is cooled to 10 DEG C,
7000rpm is centrifuged 15min；Draw upper solution to be placed in bag filter, flowing water dialysis 24h；Dialysis 24h is stood again with distilled water,
Period renews distilled water every 6h；It is eventually adding the polyethylene glycol 6000 of 4% w/v, solution is concentrated into the 1/4 of original volume；Add
Enter the Dnase I of 5% w/v, enzymolysis 0.5h at 37 DEG C, 80 DEG C of heating 5min enzyme denaturing；8000rpm is centrifuged 10min；Take supernatant, add
Entering the acetone of 2 times of volumes, overnight precipitation, 200rpm is centrifuged 2min and i.e. can get lactic acid bacteria teichoic acid.
(2) preparation of lactic acid bacteria lipoteichoic acid gel: by lactic acid bacteria lipoteichoic acid, Oligomeric maltose, powder of Radix Puerariae, hyalomitome
Acid and glycerol are sufficiently mixed according to aforementioned proportion, add distilled water pelletize 10min, make the gel of a diameter of 5mm.
Embodiment 3
A kind of lactic acid bacteria teichoic acid gel for vagina auxiliary treatment, including following raw material: lactic acid bacteria fat phosphorus
Teichaic acid 5 parts, Oligomeric maltose 50 parts, powder of Radix Puerariae 100 parts, hyaluronic acid 50 parts, glycerol 10 parts, distilled water 5000 parts.
Its preparation process is as follows:
(1) lactic acid bacteria lipoteichoic acid: lactic acid bacterial liquid is centrifugal collects thalline, takes out after being placed in liquid nitrogen freezing 1min, and room temperature is put
Putting 90s, such multigelation 5 times is with broken thalline；Add 20% phenol solution reaction 5min of 2 times of volumes of thalline, add
95% phenol solution of equivalent, water-bath 30min at 68 DEG C, period is stirred continuously；After taking-up, reactant liquor is cooled to 10 DEG C,
7000rpm is centrifuged 15min；Draw upper solution to be placed in bag filter, flowing water dialysis 48h；Dialysis 48h is stood again with distilled water,
Period renews distilled water every 6h；It is eventually adding the polyethylene glycol 6000 of 4% w/v, solution is concentrated into the 1/4 of original volume；Add
Enter the Dnase I of 5% w/v, enzymolysis 1h at 37 DEG C, 80 DEG C of heating 10min enzyme denaturing；8000rpm is centrifuged 15min；Take supernatant, add
The acetone of 2 times of volumes, overnight precipitation, 200rpm is centrifuged 2min and i.e. can get lactic acid bacteria teichoic acid.
(2) preparation of lactic acid bacteria lipoteichoic acid gel: by lactic acid bacteria lipoteichoic acid, Oligomeric maltose, powder of Radix Puerariae, hyalomitome
Acid and glycerol are sufficiently mixed according to aforementioned proportion, add distilled water pelletize 10min, make the gel of a diameter of 5mm.
Embodiment 4
Invite the curative effect evaluation test that 60 example bacterial vaginosis patients participate in 18 days by a definite date；And sign tested agreement.To suffer from
Person is randomly divided into test group and matched group 2 groups, often organizes 30 examples；Patient age is 22-45 one full year of life, course of disease 7-120 days.Two groups of patients
There was no significant difference in age, the course of disease, disease properties, there is comparability (P ＞ 0.05).Matched group uses conventional medicament first
Nitre azoles carries out treating the treatment of 7 days by a definite date；Test group adds on the basis of metronidazole treatment coagulates by the lactic acid bacteria teichoic acid of the present invention
Glue, after 7 days drug withdrawal 4 days to use metronidazole treatment, sleep preposition in vagina deep every night beginning in the 12nd day, each one, are used in conjunction 7
My god.Do not use other drug, and prohibitive life during treatment, do not do Vaginal lavages.
Before treatment, after treatment, (after matched group disables metronidazole 3 days or test group disable the present invention 3 days after) measures
Vaginal pH and draw the indexs such as vagina cleanness degree.
Curative effect determinate standard:
Recovery from illness: vaginitis symptom and sign disappear, and gynecological's training checks the vaginitis pathological manifestations disappearances such as congested, lab testing
Feminine gender, vaginal secretion cleannes I degree；
Effective: the vaginitis pathological manifestations such as vaginitis partial symptoms and sign disappear, and gynecological's training inspection is congested substantially alleviate, real
Test room check (+) or microscopy leukocyte (+), vaginal secretions cleannes II-III spend；
Invalid: vaginitis symptom does not all significantly improve with sign, even increases the weight of, or gynecological training checks the vaginitiss such as congested
Pathological manifestations is still clearly present, or lab testing (+) or microscopy leukocyte (++), or vaginal secretions cleannes IV degree.
Before treatment, the pH value of two groups of patients is above the scope of healthy vagina pH4.0-4.5；After treatment, test group 30 example
Patient's vaginal pH all recovered to normal range, and the pH of matched group 19 example patient recovered to normal range, and remaining 11 example remains above
4.5；The vaginal pH of two groups of patients is more as shown in table 1.
The vaginal pH of 1 liang of table group patient
Test group cure rate, total effective rate are higher than matched group, and difference has statistical significance (P ＜ 0.05), is shown in Table 2.Test table
Bright, the present invention can significantly improve vaginal environment, helps the recovery of microecology in vaginas, consolidates the curative effect of metronidazole.
The group clinical efficacy contrast of 2 liang of table
The foregoing is only presently preferred embodiments of the present invention, all equalizations done according to scope of the present invention patent change and repair
Decorations, all should belong to the covering scope of the present invention.
Claims (4)
1. the lactic acid bacteria teichoic acid gel for vagina auxiliary treatment, it is characterised in that: include that following weight portion is former
Material: lactic acid bacteria lipoteichoic acid 1-5 part, Oligomeric maltose 10-50 part, powder of Radix Puerariae 20-100 part, hyaluronic acid 5-50 part, glycerol 5-
10 parts, distilled water 500-5000 part.
A kind of lactic acid bacteria teichoic acid gel for vagina auxiliary treatment, it is characterised in that:
Including following raw material: lactic acid bacteria lipoteichoic acid 3 parts, Oligomeric maltose 50 parts, powder of Radix Puerariae 50 parts, hyaluronic acid 30 parts,
Glycerol 10 parts, distilled water 5000 parts.
A kind of lactic acid bacteria teichoic acid gel for vagina auxiliary treatment, its feature exists
In: the extracting method of described lactic acid bacteria lipoteichoic acid is: lactic acid bacterial liquid is centrifugal collects thalline, after being placed in liquid nitrogen freezing 1min
Taking out, room temperature places 90s, and such multigelation 3-5 time is with broken thalline；20% phenol solution adding 2 times of volumes of thalline is anti-
Answering 5min, add 95% phenol solution of equivalent, water-bath 30min at 68 DEG C, period is stirred continuously；By reactant liquor after taking-up
Being cooled to 10 DEG C, 7000rpm is centrifuged 15min；Draw upper solution to be placed in bag filter, flowing water dialysis 24-48h；Again with distillation
Water stands dialysis 24-48h, and period renews distilled water every 6h；It is eventually adding the polyethylene glycol 6000 of 4% w/v, solution is concentrated
To original volume 1/4；Add the Dnase I of 5% w/v, enzymolysis 0.5-1h at 37 DEG C, 80 DEG C of heating 5-10min enzyme denaturing；
8000rpm is centrifuged 10-15min；Taking supernatant, add the acetone of 2 times of volumes, overnight precipitation, it is the most available that 200rpm is centrifuged 2min
Lactic acid bacteria teichoic acid.
A kind of lactic acid bacteria teichoic acid gel for vagina auxiliary treatment, its feature exists
In: its preparation method is as follows: by lactic acid bacteria lipoteichoic acid, Oligomeric maltose, powder of Radix Puerariae, hyaluronic acid and glycerol according to above-mentioned
Ratio is sufficiently mixed, and adds distilled water pelletize 10min, makes the gel of a diameter of 5-8mm.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610660251.1A CN106236826A (en) | 2016-08-12 | 2016-08-12 | A kind of lactic acid bacteria teichoic acid gel for vagina auxiliary treatment |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610660251.1A CN106236826A (en) | 2016-08-12 | 2016-08-12 | A kind of lactic acid bacteria teichoic acid gel for vagina auxiliary treatment |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106236826A true CN106236826A (en) | 2016-12-21 |
Family
ID=58078068
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610660251.1A Pending CN106236826A (en) | 2016-08-12 | 2016-08-12 | A kind of lactic acid bacteria teichoic acid gel for vagina auxiliary treatment |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106236826A (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1321500A (en) * | 2001-04-23 | 2001-11-14 | 王维林 | Method for preventing and curing diseases by using kakonein preparation |
| CN1525863A (en) * | 2001-05-23 | 2004-09-01 | �Ʒ� | Lipoteichoic acid from lactic acid bacteria and its use to modulate immune responses mediated by gram-negative, potential pathogenic gram-positive bacteria |
| CN102133170A (en) * | 2010-01-21 | 2011-07-27 | 成都利济医药器械有限公司 | Bacteriostatic gel for treating and preventing vaginitis |
-
2016
- 2016-08-12 CN CN201610660251.1A patent/CN106236826A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1321500A (en) * | 2001-04-23 | 2001-11-14 | 王维林 | Method for preventing and curing diseases by using kakonein preparation |
| CN1525863A (en) * | 2001-05-23 | 2004-09-01 | �Ʒ� | Lipoteichoic acid from lactic acid bacteria and its use to modulate immune responses mediated by gram-negative, potential pathogenic gram-positive bacteria |
| CN102133170A (en) * | 2010-01-21 | 2011-07-27 | 成都利济医药器械有限公司 | Bacteriostatic gel for treating and preventing vaginitis |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN109674826A (en) | A kind of probiotic composition for nursing female reproductive system | |
| CN104450590A (en) | Bacillus subtilis with antibacterial activity and application of bacillus subtilis | |
| CN103301502A (en) | Gynecological medical gel dressing and preparation method thereof | |
| CN107998461A (en) | A kind of sheath that is exclusively used in has the function of the soluble oil of composite antibacterial | |
| CN104173871A (en) | Traditional Chinese medicine composition for treating vulvitis and applications of traditional Chinese medicine composition | |
| CN109602904A (en) | A kind of immune globulin IgY plural gel agent for gynaecological imflammation | |
| CN113274414A (en) | Probiotics preparation for repairing and maintaining vaginal microecological balance | |
| CN102335323B (en) | Traditional Chinese medicine composition for treating senile colpitis as well as preparation method and application thereof | |
| CN106236826A (en) | A kind of lactic acid bacteria teichoic acid gel for vagina auxiliary treatment | |
| CN105963807A (en) | Condom with antisepsis and anti-inflammation functions and preparation method thereof | |
| CN109771595A (en) | A kind of Chinese medicine composition and preparation method thereof for treating gynaecological imflammation | |
| CN105853463B (en) | A kind of preparation method and application for the Chinese medicine preparation treated ulcerative carbuncle ulcer, promote muscle growth | |
| CN112057601B (en) | Preparation method of active probiotic freeze-dried powder and application of active probiotic freeze-dried powder in skin and gynecological diseases | |
| CN113662998A (en) | A pharmaceutical composition for treating vaginitis and gynecological inflammation, and its preparation method | |
| CN106943444A (en) | One kind treats dermopathic pharmaceutical composition and its production and use | |
| CN103623286B (en) | A kind of Chinese herbal medicine for the treatment of genital herpes | |
| CN105287955A (en) | Traditional Chinese medicine preparation used for treating jaundice and preparation method | |
| CN104688823B (en) | Antipruritic Chinese medicine composition of a kind of anti-inflammation and preparation method thereof | |
| CN101686992B (en) | Use of extractive of BCG polysaccharide and nucleic acid for preparing medicine for treating allergic dermatosis, and its injection and preparation method | |
| CN1739538A (en) | Suppository for teating mycotic vaginitis | |
| CN107362310A (en) | It is a kind of to be used to repair Baicao Fuyanqing preparation of vagina environment and preparation method thereof | |
| CN103751226A (en) | Application of Yishenkang Capsules in preparing medicaments for treating hepatitis | |
| CN103961586B (en) | A kind of medicine treating vulvitis and preparation method | |
| CN100340263C (en) | Suppository for treating bacterial vaginitis | |
| CN105168638A (en) | Traditional Chinese medicinal liquid band aid for preventing and treating bedsore complicated with bacterial infection |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20170623 Address after: 350200 Fujian city of Fuzhou province Changle City Jinfeng town six village forest tycoon 166 Applicant after: Zhang Kechi Address before: 350015 (), room 1#2-4N, No. 27, Lake Road, Mawei District, Fujian, China Applicant before: Fujian trillion ecommerce Co., Ltd of shop-within-a-shop |
|
| TA01 | Transfer of patent application right | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20161221 |
|
| RJ01 | Rejection of invention patent application after publication |